N/A N=87 Evaluation of Vitrectomy for Diabetic Macular Edema
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Visual Acuity — 52 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=205 Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) — 59.3; 63.0 units on a scale
N/A N=126 Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: Recurrent VH Incidence (Early and Late) — 22.2; 10.8; 32.4; 11.1 Percentage of participants — p=<0.05
Phase 1 N=40 Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
Intravitreal Bevacizumab Injection · Pars Plana Vitrectomy · Tractional Retinal Detachment
Primary: Best Corrected Visual Acuity — 1.1; 1.4 LogMar
Phase 2 N=12 Aflibercept Injection for Proliferative Diabetic Retinopathy
Vitreous Hemorrhage
Primary: Rate of Resolved Post-operative Vitreous Hemorrhage. — 6; 5 Participants
Phase 2 N=24 Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
Vitrectomy
Primary: Percentage of Eyes With Total Macular Posterior Vitreous Detachment (PVD). — 50; 62.5 percentage of eyes — p=0.679
Phase 4 N=30 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
Diabetic Macular Edema · Epiretinal Membrane
Primary: Central Retinal Thickness — 350 micrometers
Phase 2 N=125 A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
Vitrectomy
Primary: Proportion of Patients Achieving Total Posterior Vitreous Detachment (PVD) Without Creation of an Anatomical Defect — 13.8; 18.2; 31.3; 10 percentage of participants…
N/A N=35 Effects of Pneumatic Vitreolysis on Macular Hole
Vitreomacular Traction (VMT) · Full-thickness Macular Holes (MH)
Primary: Proportion of Eyes With Macular Hole Closure of Inner Retinal Layers Without Rescue Vitrectomy — 10 Eyes
Phase 3 N=46 Effects of Pneumatic Vitreolysis on Vitreomacular Traction
Vitreomacular Traction
Primary: Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy — 78; 9 percentage of eyes
Phase 2 N=56 Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema
Diabetic Macular Edema · Vitrectomy
Primary: Change From Baseline in Central Retinal Thickness in the Study Eye — 403.4; -38.9 Microns
N/A N=25 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Vitrectomy
Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants
Phase 4 N=52 Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
Vitreomacular Traction · Vitreomacular Adhesion
Primary: Percentage of Subjects With Non-surgical Resolution of Focal VMT/sVMA at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain Optical Coherence…
Phase 4 N=69 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy · Diabetic Traction Retinal Detachment · Vitreous Hemorrhage
Primary: Reoperation — 1; 7 participants — p=0.033
Phase 2 N=296 Bevacizumab Against Recurrent Retinal Detachment
Retinal Detachment · Proliferative Vitreoretinopathy
Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants
Phase 3 N=261 Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
Vitreous Hemorrhage · Proliferative Diabetic Retinopathy
Primary: Treatment or "Failure" Defined as Vitrectomy — 12; 17 percentage of participants — p=0.37
Phase 3 N=220 Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Vitreomacular Adhesion Including Macular Hole
Primary: Proportion of Subjects With Pharmacological Vitreomacular Adhesion (VMA) / (Vitreomacular Traction [VMT]) Resolution at Day 28 — 41.7; 6.2 Percentage (weighted across…
N/A N=136 Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes
Vitreoretinal Disease
Primary: Mean Change in Intraocular Pressure (IOP) on Operative Day — -0.40; -3.05 mmHG
Phase 3 N=172 A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
Symptomatic Vitreomacular Adhesion
Primary: Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA) — 52.2; 1.8 percentage of subjects
Phase 3 N=326 Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
Vitreomacular Adhesion
Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28 — 25.3; 6.2 percentage of participants — p=<0.001
Phase 4 N=57 Postoperative Pain Control Following Vitreoretinal Surgery
Retinal Detachment · Proliferative Vitreoretinopathy · Retinoschisis
Primary: Mean Pain Score — 2.9; 3.8 units on a scale
Phase 4 N=468 Assessment of Patients Treated With JETREA® for Vitreomacular Traction
Vitreomacular Traction · Vitreomacular Adhesion
Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Traction (VMT/VMA) at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain…
N/A N=118 Next Generation Cataract and Vitreoretinal Surgery Study
Vitreoretinal Disease With or Without Cataracts
Primary: Percent of 'Yes' Responses to the Binary Question: "Did UNITY VCS Using Vitreoretinal or Combined Surgical Functionality Perform Per the Intended Use as Defined in…
N/A N=40 Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe
Vitrectomy
Primary: Time to Completion of Core Vitrectomy and Shave of Vitreous Base — 9.7; 10.4 minutes
N/A N=19 Avastin for PDR (Proliferative Diabetic Retinopathy)
Retinal Detachment · Diabetic Retinopathy
Primary: The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction…
Phase 4 N=112 Isotretinoin for Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy
Primary: Rate of Retinal Attachment — 50; 42 Participants
Phase 3 N=406 Intravitreal Aflibercept Injection in Vision Impairment Due to DME
Diabetes Mellitus · Macular Edema
Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…
N/A N=78 Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes
Idiopathic Macular Hole
Primary: Visual Acuity (ETDRS Letters) — 74.9; 72.4; 72.2 Visual acuity in letters
N/A N=20 Visual Outcomes and Patient Satisfaction With Vivity IOL in Post Refractive Patients
Pseudophakia
Primary: Binocular Best Corrected Distance Visual Acuity — -0.05 logMAR
Phase 2 N=30 Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
Diabetic Retinopathy
Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants